Skip to content
relates to Merck’s Little Brown Pill Could Transform the Fight Against Covid

Illustration: 731

Merck’s Little Brown Pill Could Transform the Fight Against Covid

The antiviral drug molnupiravir, still in clinical trials, would give doctors an important new treatment and a weapon against coronaviruses and future pandemics

Updated on

The story of what might become the next major breakthrough in Covid-19 treatment starts on a hotel hallway floor in January 2020, months before you were worried about the virus, weeks before you likely knew it existed. A scientist and a business executive were at a health-care conference in San Francisco, hatching a plan to get a promising drug out of academia and into research trials for regulatory approval. George Painter, president of the Emory Institute for Drug Development, and Wendy Holman, chief executive officer of Ridgeback Biotherapeutics, had met at the Handlery Union Square Hotel to discuss a compound Painter had started developing with funding from the National Institutes of Health. They got so enthusiastic about the possibilities that their meeting ran long and a group of lawyers kicked them out of their room. So they continued on the hall floor, hours after they’d started.

Megaphone.fm: How About a Covid Pill? by Listen to ...